Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy
ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (âQuoinâ or the âCompanyâ), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization.
Related Questions
How will the new CFO's experience influence Quoin Pharmaceuticals' financial strategy and capital allocation for QRX003 commercialization?
What are the expected shortâterm and longâterm effects of this leadership change on QNRX's stock liquidity and valuation?
Will the appointment signal upcoming financing activities (e.g., equity raises, debt issuance) or partnerships that could impact the company's balance sheet and share dilution?